Premium
The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders — a double‐blind placebo‐controlled study
Author(s) -
Björk K.
Publication year - 1983
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1983.tb11122.x
Subject(s) - placebo , double blind , psychiatry , depressive symptoms , major depressive disorder , medicine , psychology , placebo controlled study , alternative medicine , anxiety , pathology , cognition
— The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders was evaluated in a randomized, placebo‐controlled study involving 40 patients. The intended study period was 18 months. The results showed zimeldine to be significantly more effective than placebo, both in terms of preventing recurrence (t‐test: P < 0.001) and the withdrawal rate (Cox's test: P < 0.01). Adverse symptoms for zimeldine did not differ from placebo. There were no noteworthy changes in clinical chemistry, blood pressure, ECG and pulse rate.